LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Micro- and Nanotechnology in Vaccine Development
- 1st Edition - September 20, 2016
- Editors: Mariusz Skwarczynski, Istvan Toth
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 3 9 9 8 1 - 4
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 4 0 0 2 9 - 9
This book provides a comprehensive overview of how use of micro- and nanotechnology (MNT) has allowed major new advance in vaccine development research, and the challenges that im… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThis book provides a comprehensive overview of how use of micro- and nanotechnology (MNT) has allowed major new advance in vaccine development research, and the challenges that immunologists face in making further progress.
MNT allows the creation of particles that exploit the inherent ability of the human immune system to recognize small particles such as viruses and toxins. In combination with minimal protective epitope design, this permits the creation of immunogenic particles that stimulate a response against the targeted pathogen. The finely tuned response of the human immune system to small particles makes it unsurprising that many of the lead adjuvants and vaccine delivery systems currently under investigation are based on nanoparticles.
- Provides a comprehensive and unparalleled overview of the role of micro- and nanotechnology in vaccine development
- Allows researchers to quickly familiarize themselves with the broad spectrum of vaccines and how micro- and nanotechnologies are applied to their development
- Includes a combination of overview chapters setting out general principles, and focused content dealing with specific vaccines, making it useful to readers from a variety of disciplines
Academic (researchers and grad students); Investigators in translational research; clinical scientists; pharmaceutical companies and development laboratories
- No. of pages: 460
- Language: English
- Edition: 1
- Published: September 20, 2016
- Imprint: Elsevier
- Hardback ISBN: 9780323399814
- eBook ISBN: 9780323400299
MS
Mariusz Skwarczynski
Mariusz Skwarczynski completed his Ph.D. in Chemistry in 1999 at Wroclaw University of Technology. His postdoctoral training began at Tokushima Bunri University under the direction of Professor M. Nishizawa, where he studied the biomimetic total synthesis of anticancer agent paclitaxel. He then joined the laboratory of Professor Yoshiaki Kiso at Kyoto Pharmaceutical University to study prodrugs of paclitaxel. In 2004 he was awarded with prestigious Japanese fellowship (Japan Society for the Promotion of Science postdoctoral fellowship) and research grant to conduct further research on paclitaxel. He developed novel classes of paclitaxel prodrugs: isotaxoids and phototaxels. He also developed an epimerization-free method for the synthesis of novel building blocks (isodipeptides) for solid phase peptide synthesis and these units have been commercialized by Merck-Novabiochem. In 2008 he joined Professor Istvan Toth group at University of Queensland to work on drug, gene and vaccine delivery strategies. Since then he research is mainly focused on nanotechnology-based vaccine delivery approaches. He has published over 60 peer-reviewed publications, 4 book chapters, and other 100 conference abstracts. Currently he is Vice-Chancellor Fellow at University of Queensland.
Affiliations and expertise
Vice-Chancellor and Fellow, University of Queensland, AustraliaIT
Istvan Toth
Professor Toth is a chemical engineer with a research focus on medicinal chemistry. He was awarded his PhD in 1972 and has since worked in Hungary, Canada and the United Kingdom before relocating to Australia in 1998. His major research interests are drug delivery, immunoadjuvants, synthetic vaccines and gene delivery. His research has attracted over $60 million in competitive grants, research contracts and investment funds in the past 10 years. He has over 300 peer-reviewed publications, 43 patents, and an excellent track record in research commercialization as a key founder of Alchemia (ASX listed), Implicit Bioscience Pty Ltd, Neurotide Pty Ltd and TetraQ (the commercial arm of Centre of Integrated Preclinical Drug Development).
Affiliations and expertise
ARC Australian Professorial Fellow, Chair in Biological Chemistry, Professor of Pharmacy, Group Leader, IMB Division of Structural BiologyRead Micro- and Nanotechnology in Vaccine Development on ScienceDirect